“The pharmaceutical industry is pretty unusual in that 95 per cent of what it does fails”*

We can't better start why we codename Green PHARMA.I. the new paradigm we ambition to introduce.
What make green-CODD so disruptive ? We want to select the medicinal recipe that work in developing countries naturopathy for years and turn them, thanks to partnership (s) with major pharmaceutical actor (Merck !), into FDAble (and also European Medicines Agency-approved) medicament.
In a few words ''green-drugs'' conceptualization exploit the reducing of creating drugs process length & cost allowed by the introduction of Artificial Intelligence & Machine Learning in the medicament-making process.
Moreover we want to launch in market Nature-based drugs whose profitability & ''vital'' efficiency will be higher than the previous models (allopathic-medicine) ones : respectively only 5%* & 3% ( ROI,only !)

''Onco-509 is the new Epidiolex''

As we want to revolutionize the concept of ''dr...
“The pharmaceutical industry is pretty unusual in that 95 per cent of what it does fails”*

We can't better start why we codename Green PHARMA.I. the new paradigm we ambition to introduce.
What make green-CODD so disruptive ? We want to select the medicinal recipe that work in developing countries naturopathy for years and turn them, thanks to partnership (s) with major pharmaceutical actor (Merck !), into FDAble (and also European Medicines Agency-approved) medicament.
In a few words ''green-drugs'' conceptualization exploit the reducing of creating drugs process length & cost allowed by the introduction of Artificial Intelligence & Machine Learning in the medicament-making process.
Moreover we want to launch in market Nature-based drugs whose profitability & ''vital'' efficiency will be higher than the previous models (allopathic-medicine) ones : respectively only 5%* & 3% ( ROI,only !)

''Onco-509 is the new Epidiolex''

As we want to revolutionize the concept of ''drugs'' , our most valuable performance indicator as BetoBe start-up is the number of ongoing success-story that we have to show, it's why we decide to enter a U$ 20 billion worldwide lung cancer healing-market to write our first success-story.
Onco-509 can represent for us what Office bring to Microsoft Windows 1995 : a bankable success-story and proof-concept.
It's why we select an oncologic treatment that Work and doesn't exist in the current lung cancer literature, a perfect showcase where we will have : a) to test its ''medicamentality'' (Phase I) thanks to newest artificial-intelligence tools company (like Inato) to make it a FDA-approved drug* like Epidiolex, a Nature-based medication authorized since June 15th,2018 for the US market, whose active ingredient is CannaBiDiol [CBD] that is effective as child epileptic therapy.
Our revenue-model will be License-based : Phase II will be to figure out the active ingredients that have worked so well in Benin, Brazil, Haiti... with the tools of : a) on line database of natural compound
b) Partnership with Cyclica (we already have contacts) and/or BioXplor an augmented intelligence platform for data-driven hypotheses generation in drug discovery
Phase III : clinical trials
Phase IV : FDA +/- review & Delivering (or not) of Licenses
PS* : Jackie Hunter, Benevolent AI CEO.
More information

Employees

Ricardo Polycarpe
Admin
Ricardo Polycarpe CEO "Risk-Taker so Dream-maker" : an entrepreneurial life.